"You'll notice in the company's most recent guidance they expect the trial to end sometime in H1 of 2019. Therefore it's been pushed back considerably."

Not necessarily. Q1 2019 lies within H1 2019. Simply changing Q1 2019 to H1 2019 does not mean that Q1 2019 is not still in play. Perhaps the prediction is right on the line of the Q1/Q2 interface, which makes a H1 2019 statement safer. Also, trial completion is a broad statement that could be defined differently: hitting 250 events/end of dosing, last patient follow up visit, adjudication completion, data base lock, top-line data release. Which one is it that you (or Resverlogix) are referring to?

"Based on our crude model, we would expect the 250th event to occur sometime in March with the potential to stretch into April."

I have no idea what your crude model is. However, if 250th event and last dosing don't occur until March or April, then most likely top-line data will stretch into Q3 due to time required for last patient visits, adjudication and data base clean up/locking. But as I wrote in my last post, previous guidance suggests hitting 250 events by Feb 12th.....much earlier than your prediction. 

"This is based off either assuming EXAMINE's patient population as placebo which gives a RRR of 43%. Or if you assume the patient population has 10% lower MACE rates you still get a RRR of 30% and a similar range of dates. I would expect the company to find financing here to pay loan back. Note these estimates are based off the 200th MACE happening just prior to the September 12th conference call."

Now you're just talking silly by assuming that you can predict a RRR% with any certainty based upon the big unknown of the placebo event rate in BETonMACE.  

BearDownAZ